MARKET WIREReuters • 2h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
Why VBIO Stock dropped -9.13% Today — RQD Quant Desk Flash
$0.62 -9.13% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.61
Valion Bio Inc. (VBIO) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $1.3M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.61 (-1.83%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-6.5% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VBIO)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (44/100 Composite)
🔍 WHY VBIO SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (25% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (23% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$2.14-45.3% Next Q
52
Q2 (-2Q)Grade D$1.17-19.7% Next Q
49
Q3 (-1Q)Grade D$0.94-34% Next Q
47
CurrentGrade D$0.62-6.5% Hist 90D α
44
Trajectory: C- (52) → D (44)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a VBIO Turnaround Squeeze
While VBIO currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.23) and Max Pain ($0.65) forces dealer call-delta covering toward $70.88.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $VBIO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “VBIO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why VBIO Stock dropped -9.13% Today — RQD Quant Desk Flash
Valion Bio Inc. (VBIO) dropped -9.13% to $0.62, trading at 2% of its 52-week range ($0.52 – $67.5). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($0.52 – $67.5) with RSI-14 at 20.1 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.62 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live VBIO Headlines & Catalysts
MARKET WIRECNBC • 4h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 4h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 5h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 6h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 7h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 8h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 8h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VBIO)
- ✓Walkthrough of VBIO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
VBIO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -97.47%📐 HORIZONTAL RANGE
2026-10-30O $0.60H $0.62L $0.52C $0.62VOL 217.6K
RES: $34.69SUP: $-7.88SMA50: $2.23SMA200: $15.10
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
VBIO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on VBIO today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for VBIO. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for VBIO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VBIO)
Health Care Rank #534 of 1016
⚔️ NXL vs VBIO Full Matrix →
1. Head-to-Head Health Care Peer Comparison (VBIO vs. NXL, NUWE, NDRA, IRIX)
Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Valion Bio Inc. (VBIO) ranks #534 by composite RQD confidence (44/100, grade D) and #1013 by equity capitalization ($1.3M). Within this direct 5-issuer industry benchmark cohort, VBIO leads on earnings valuation at N/A trailing P/E, while VBIO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. NDRA currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with VBIO at 44/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| VBIO
ACTIVE
Valion Bio Inc. | D | 44/100 | — | — | -35.0% | -9.13% | $1.3M | Benchmark Subject |
| NXL Nexalin Technology Inc. | D- | 37/100 | — | 79.7% | -35.0% | 0.00% | $1.9M | /nxl-vs-vbio → |
| NUWE Nuwellis Inc. | D | 45/100 | — | 62.0% | -35.0% | +2.12% | $2.3M | /nuwe-vs-vbio → |
| NDRA ENDRA Life Sciences Inc. | D | 48/100 | — | — | -35.0% | +2.95% | $7.3M | /ndra-vs-vbio → |
| IRIX IRIDEX Corporation | E | 34/100 | — | 36.5% | -35.0% | -2.92% | $12.7M | /irix-vs-vbio → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001787740In its most recent audited fiscal period (FY2025, filed 2025-12-31), Valion Bio Inc. (VBIO) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $780.0K , and -100.0% cumulative change since FY2023) , GAAP net income of -$8.9M, operating cash flow of -$7.0M, and free cash flow of -$7.0M (-22.9% YoY). On the balance sheet, VBIO closed FY2025 with $31.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$8.9M | -$7.0M | -$7.0M | $31.6M | — |
| FY2024 (FY) | 2024-12-31 | $780.0K | -$5.7M | -$5.7M | -$5.7M | $2.8M | — |
| FY2023 (FY) | 2023-12-31 | $1.2M | -$8.2M | -$8.5M | -$8.5M | — | — |
3. VBIO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs VBIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Valion Bio Inc. (NASDAQ: VBIO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $0.62 (-9.13% 1D, market cap $1.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, VBIO ranks #534 in composite RQD confidence.
How does VBIO compare to NXL and NUWE in the Health Care sector?
Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), VBIO carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NXL (Nexalin Technology Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $1.9M) and NUWE (Nuwellis Inc.) posts a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $2.3M). Among the 5-stock peer group, VBIO leads on earnings multiple (N/A) while VBIO leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for VBIO?
Per VBIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001787740), Valion Bio Inc. generated $0 in revenue (-100.0% YoY), -$8.9M in net income, and -$7.0M in free cash flow against $31.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is VBIO trading relative to its 50-day, 200-day, and 52-week technical levels?
VBIO last traded at $0.62 (-9.13% on volume of 140,013 shares), positioning the stock -72.20% below its 50-day simple moving average ($2.23) and -95.89% below its 200-day simple moving average ($15.10). Across its 52-week range of $0.52 to $67.50, VBIO sits at the 0.1% percentile with a 14-day RSI of 20.1 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.70).
VBIO Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is VBIO stock moving today?
Why VBIO Stock dropped -9.13% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.